Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Conditions:Lung Cancer, Lung Cancer, Lung Cancer, Ovarian Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:August 11, 2015

Use our guide to learn which trials are right for you!

Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

This phase I/II trial studies the side effects and the best dose of methoxyamine when given
together with cisplatin and pemetrexed disodium and to see how well it works in treating
patients with solid tumors or mesothelioma that have spread to other places in the body and
usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma
that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory).
Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work
better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as
cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a
better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.


I. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for
the combination of methoxyamine (TRC102) with pemetrexed (pemetrexed disodium) and cisplatin
in patients with advanced solid tumors. (Arm A) II. To describe the toxicities of TRC102
combined with pemetrexed and cisplatin at each dose studied. (Arm A) III. To describe
responses to the drug combination at each dose level. (Arm A) IV. To detect activity of the
combination of TRC102 and pemetrexed, as evidenced by tumor response in patients with
advanced malignant mesothelioma previously treated with pemetrexed and cisplatin. (Arm B)


I. To describe pharmacokinetic parameters of TRC102 given concurrent with pemetrexed and

II. To evaluate the pharmacodynamic parameters of TRC102 given concurrently with pemetrexed
and cisplatin.

III. To explore the feasibility of establishing pleural and peritoneal effluent-derived cell
lines and to evaluate the response of cultured pleural and peritoneal mesothelioma cells to
cisplatin, pemetrexed, and TRC102.

IV. To document all objective clinical responses to TRC102 in combination with pemetrexed and

OUTLINE: This is a phase I, dose-escalation study of methoxyamine, followed by a phase II
study. Patients are assigned to 1 of 2 treatment arms.

ARM A: Patients receive methoxyamine orally (PO) once daily (QD) on days 1-4, pemetrexed
disodium intravenously (IV) over 10 minutes, and cisplatin IV over 30-60 minutes on day 1.
Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or
unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond
cycle 6 if the patient continues to benefit from treatment at the discretion of the treating

ARM B: Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10
minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of
disease progression or unacceptable toxicity. Patients may continue methoxyamine and
pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the
discretion of the treating physician.

After completion of study treatment, patients are followed up for 8 weeks.

Inclusion Criteria:

- Arm A dose escalation: patients with histologically or cytologically proven advanced
solid tumors for which standard treatments are not available, or for whom the current
dose level of cisplatin in combination with pemetrexed is appropriate; =< 2 prior
cytotoxic chemotherapy regimen

- Arm A dose level 4 (75 mg/m^2 cisplatin): patients with histologically proven
chemotherapy-naive advanced unresectable solid tumors for which pemetrexed combined
with cisplatin is an indicated regimen

- Arm B (first stage of phase II of TRC102 and pemetrexed): patients with malignant
pleural or peritoneal mesothelioma who had progressed while being treated with or had
recurred within 6 months of being treated with pemetrexed and cisplatin or carboplatin
frontline; intervening treatment is allowed

- Prior pemetrexed is allowed except Arm A dose level 4 (cisplatin 75 mg/m^2)

- Eastern Cooperative Oncology Group (ECOG) performance status 0 -1 (Karnofsky >= 70%)

- Life expectancy of greater than 3 months

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Hemoglobin >= 10.0 g/dl

- Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of
normal (ULN)

- Total bilirubin < 1.5 x ULN

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 x institutional ULN or =< 5 x ULN if metastatic disease involves liver

- Serum creatinine =< 1.5 x ULN or a calculated creatinine clearance >= 60 ml/min/1.73
m^2 (Cockcroft-Gault method) for patients receiving combination of cisplatin and
pemetrexed and >= 45 ml/min/1.73 m^2 for patients receiving pemetrexed; 24 hour urine
for creatinine clearance is acceptable if the calculated creatinine clearance is

- For patients enrolled in arm B (first stage of phase II of TRC102 and pemetrexed)
measurable disease is required according to the Response Evaluation Criteria in Solid
Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria
as described by Byrne and Novak for patients with malignant pleural mesothelioma;
pleural effusion and ascites are not considered measurable disease

- Patients must be able to swallow whole capsules; nasogastric or gastrointestinal
(G)-tube administration is not allowed

- The effects of TRC102 on the developing human fetus are unknown; for this reason and
because TRC102 as well as other therapeutic agents used in this trial are known to be
teratogenic, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry, for the duration of study participation, and 4 months after completion of the
study drugs; should a woman become pregnant or suspect she is pregnant while she or
her partner is participating in this study, she should inform her treating physician
immediately; men treated or enrolled on this protocol must also agree to use adequate
contraception prior to the study, for the duration of study participation, and 4
months after completion of TRC102, pemetrexed and cisplatin administration;
non-childbearing potential is defined as (by other then medical reasons): >= 45 years
of age and has not had menses for >= 2 years, amenorrheic for < 2 years without
hysterectomy and oophorectomy and a follicle-stimulating hormone value in the
postmenopausal range upon pretrial (screening) evaluation, or post hysterectomy,
oophorectomy or tubal ligation; documented hysterectomy or oophorectomy must be
confirmed with medical records of the actual procedure or confirmed by ultrasound;
tubal ligation must be confirmed with medical records of the actual procedure
otherwise the patient must be willing to use 2 adequate barrier methods throughout the
study, starting with the screening visit though 4 months after the last dose of study

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier;
patients who have had targeted therapy will be required to wait 2 weeks due to short
half-life of the drugs; treatment with bisphosphonates is permitted

- Patients who are receiving any other investigational agents

- Patients with active brain metastases or carcinomatous meningitis are excluded from
this clinical trial; patients with treated brain metastases, whose brain metastatic
disease has remained stable for greater than or equal to 4 weeks without requiring
steroid and anti-seizure medications are eligible to participate

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to TRC102 or pemetrexed and cisplatin

- No studies have been performed to assess potential metabolic and transport
interactions of TRC102; as part of the enrollment/informed consent procedures, the
patient will be counseled on the risk of interactions with other agents, and what to
do if new medications need to be prescribed or if the patient is considering a new
over-the-counter medicine or herbal product; the case report form must capture the
concurrent use of all other drugs, over-the-counter medications, or alternative

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because TRC102 is agent with the potential
for teratogenic or abortifacient effects; because there is an unknown but potential
risk for adverse events in nursing infants secondary to treatment of the mother with
TRC102, breastfeeding should be discontinued if the mother is treated with TRC102;
these potential risks may also apply to other agents used in this study

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible because of the potential for pharmacokinetic interactions with
TRC102; in addition, these patients are at increased risk of lethal infections when
treated with marrow-suppressive therapy; appropriate studies will be undertaken in
patients receiving combination antiretroviral therapy when indicated

- Patients with known disorders associated with hemolysis

- Patients with thromboembolic disease and on anticoagulation

- Patients with a prior cumulative cisplatin dose > 300 mg/m^2 (pertains to Arm A only)
We found this trial at
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Ticiana A. Leal
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Madison, WI
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Marianna Koczywas
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Duarte, CA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Ann Arbor, MI
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Principal Investigator: Stephen Leong
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Aurora, CO
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Principal Investigator: Edward A. Sausville
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Baltimore, MD
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Gregory A. Otterson
Phone: 800-293-5066
Columbus, OH
Click here to add this to my saved trials
1983 Marengo St
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Anthony El-Khoueiry
Phone: 323-865-0451
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
Los Angeles, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Anthony El-Khoueiry
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Leora Horn
Phone: 800-811-8480
Nashville, TN
Click here to add this to my saved trials
Pasadena, California 91105
Principal Investigator: Anthony El-Khoueiry
Phone: 323-865-0451
Pasadena, CA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Liza C. Villaruz
Phone: 412-647-8073
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Aaron S. Mansfield
Phone: 855-776-0015
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Karen L. Kelly
Phone: 916-734-3089
Sacramento, CA
Click here to add this to my saved trials